%20(2).png)
GLP-1 medications are beginning to influence more than the health and pharmaceutical sectors. As their use grows, they are also changing how people shop, eat and think about food.
A growing number of users report eating more protein and fibre, as well as reducing their portion sizes. These changing habits present a significant consideration for food manufacturers and product development teams.
GLP-1 medications can reduce appetite, meaning many users eat less at each occasion and may favour smaller meals more frequently.
For product developers, the opportunity is not simply to make existing products smaller. Consumers may expect a reduced portion to provide meaningful nutrition, remain satisfying and still offer good value for money.
This could support further innovation across portion-controlled ready meals, smaller snacks and single-serve formats. Packaging may also need to evolve, with greater emphasis on resealability, portion guidance and formats that help minimise food waste.
High-protein innovation was already well established before the growth of GLP-1 medications. However, changing eating patterns are likely to strengthen demand for products that deliver more nutritional value within a smaller serving.
Protein can be incorporated across a growing range of categories, from ready meals and breakfast products to snacks, desserts and drinks. Fibre, wholegrains and nutrient-dense ingredients are also likely to become increasingly important.
The challenge for NPD teams will be to achieve this without compromising taste, texture, convenience or affordability. Consumers may want products with stronger nutritional credentials, but enjoyment will continue to influence repeat purchases.
The effect of GLP-1 use may extend beyond the individuals taking the medication. As household eating habits change, families may begin choosing different portion sizes, buying fewer traditional snacks or looking for products that feel lighter while still offering satisfaction.
Categories associated with impulse purchases and larger portions may face challenges. However, this does not necessarily mean consumers will stop buying indulgent food. Instead, they may choose it less frequently, in smaller quantities or with a greater focus on quality.
Premium miniature products and individually portioned treats could therefore become more relevant as consumers look to enjoy familiar foods in a way that better suits their appetite.
Some manufacturers have already introduced products specifically intended for people using GLP-1 medications, including portion-controlled meals containing protein, fibre and essential nutrients.
Other businesses may take a less direct approach, developing products around the associated consumer needs without explicitly positioning them for GLP-1 users.
This could have broader appeal and avoid making products feel overly clinical. Smaller portions, higher protein, increased fibre and balanced nutrition are relevant to many consumers, regardless of whether they use weight-management medication.
GLP-1 medications are unlikely to create one clearly defined food category. Their greater influence may be seen across many existing categories as manufacturers reconsider portion sizes, nutritional density and the role of different eating occasions.
For NPD and Technical teams, key areas of focus could include:
GLP-1 use is still developing, and its long-term effect on the UK food market remains to be seen. However, it is already encouraging an important shift in food innovation: away from simply offering more and towards delivering greater value, enjoyment and nutrition in every portion.
